Form D · Biotechnology
SUTRO BIOPHARMA INC
South San Francisco, CA · CIK 0001382101
Offering snapshot reported Aug 8, 2018 · SEC filing
- Reported sold
- $85.4M Offering amount: $85.4M
- Investors reported
- 15 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 24, 2018 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$31,624,999 → $85,382,349
- Reported investors8 → 15
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 8, 2018 | Amendment | $85,382,349 | $53,757,350vs Jun 6, 2018 | 15 | SEC filing |
| Jun 6, 2018 | Initial | $31,624,999 | No comparison | 8 | SEC filing |
| Oct 24, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Dec 29, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Nov 8, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-314024
Source: Form D, filed Aug 8, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Dybbs | Director |
| John G. Freund | Director |
| Daniel Janney | Director |
| Bryan Lawlis | Director |
| Virgil Bryan Lawlis | Director |
| Joseph Lobacki | Director |
| William J. Newell | Director, Executive |
| Daniel Petree | Director |
| Michael Ross | Director |
| Armen Shanafelt | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
310 Utah Ave., Suite 150
South San Francisco, CA, 94080
South San Francisco, CA, 94080